Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for prostate cancer.

B I Rini1, E J Small

  • 1University of California at San Francisco Comprehensive Cancer Center, 1600 Divisidero Street, 3rd floor, San Francisco, CA 94115, USA. brini@medicine.ucsf.edu

Current Oncology Reports
|August 8, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.

ESMO open·2023
Same author

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
Same journal

Current Understanding of CHIP's Immunobiological Footprint with A Focus on Gastrointestinal Disorders: A Review of the Literature.

Current oncology reports·2026
See all related articles

Recent advances explain immune response components and their dysfunction in cancer, leading to immunotherapies. While these strategies show promise in prostate cancer, clinical success remains limited.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Effective immune responses involve multiple components.
  • Immune response dysfunction is a hallmark of cancer.
  • Understanding these dysfunctions informs therapeutic strategies.

Purpose of the Study:

  • To review current immunotherapeutic approaches for cancer.
  • To highlight strategies targeting immune components in prostate cancer.
  • To assess the clinical success of these immunotherapies.

Main Methods:

  • Review of recent scientific literature on cancer immunology and immunotherapy.
  • Analysis of therapeutic strategies including dendritic cell stimulation, antigen presentation, and antibody therapy.
  • Evaluation of clinical outcomes in prostate cancer treatment.

Related Experiment Videos

Main Results:

  • Several immunotherapeutic strategies have been developed to modulate the immune response against cancer.
  • Approaches targeting dendritic cell proliferation, antigen processing, and effector cell activation are prominent.
  • Prostate cancer immunotherapies have successfully induced immune responses, but clinical efficacy is limited.

Conclusions:

  • Elucidation of immune components has spurred novel cancer immunotherapies.
  • Targeting immune dysfunction offers a promising avenue for cancer treatment, particularly in prostate cancer.
  • Further research is needed to improve the clinical success of cancer immunotherapies.